Outcome of Fertility-preserving Treatment in Young Women with Endometrial Carcinomas

Overview

Journal BJOG

Specialty Gynecology & Obstetrics

Date 2005 Feb 17

PMID 15713146

Citations 29

Authors

K Niwa

K Tagami

Z Lian

K Onogi

H Mori

T Tamaya

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the outcome of conservative treatment of young women with endometrial cancer.

Design: Observational study.

Setting: Gifu University Hospital, Japan from 1988 to 2002.

Population: Twelve women with endometrial cancer, FIGO IA estimated by MRI under 35 years.

Methods: Patients were treated with medroxyprogestreone acetate (400-600 mg/day) for 6-10 months, with endometrial curettage performed every four weeks.

Main Outcome Measures: Response to therapy, pregnancies and reoccurrence of disease during follow up over a 30-month period.

Results: All cases had pathological complete remissions within 6-10 months. Seven of 10 wishing to have babies conceived, and five of them were delivered of full-term babies. Eight of nine cases receiving long term follow up (over 30 months) developed recurrent disease, with four opting for hysterectomy. No patient developed distant metastases or had disease-related death.

Conclusion: Conservative therapy is feasible in carefully selected young women with endometrial cancer. Recurrence rates were high during long term observation even after pathological complete remissions. Therefore, close follow up is recommended.

Citing Articles

Upgrading Treatment and Molecular Diagnosis in Endometrial Cancer-Driving New Tools for Endometrial Preservation?.

Dellino M, Cerbone M, Lagana A, Vitagliano A, Vimercati A, Marinaccio M Int J Mol Sci. 2023; 24(11).

PMID: 37298731 PMC: 10253366. DOI: 10.3390/ijms24119780.

Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.

Murakami I, Machida H, Morisada T, Terao Y, Tabata T, Mikami M J Gynecol Oncol. 2023; 34(4):e49.

PMID: 36929578 PMC: 10323306. DOI: 10.3802/jgo.2023.34.e49.

Effectiveness of Megestrol for the Treatment of Patients with Atypical Endometrial Hyperplasia or Endometrial Endometrioid Adenocarcinoma (Stage IA, Well Differentiated).

Akhavan S, Sabet F, Mousavi A, Gilani M, Hasani S J Res Pharm Pract. 2022; 10(3):138-143.

PMID: 35198507 PMC: 8809456. DOI: 10.4103/jrpp.JRPP_20_128.

Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.

Herrera Cappelletti E, Humann J, Torrejon R, Gambadauro P Hum Reprod Update. 2021; 28(2):282-295.

PMID: 34935045 PMC: 8888991. DOI: 10.1093/humupd/dmab041.

Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.

Fan Y, Li X, Wang J, Wang Y, Tian L, Wang J Reprod Biol Endocrinol. 2021; 19(1):118.

PMID: 34344384 PMC: 8330111. DOI: 10.1186/s12958-021-00808-y.